MY208422A - Combination therapy of pd-1-targeted il-2 variant immunocytokines and antibodies against human pd-l1 - Google Patents

Combination therapy of pd-1-targeted il-2 variant immunocytokines and antibodies against human pd-l1

Info

Publication number
MY208422A
MY208422A MYPI2020004677A MYPI2020004677A MY208422A MY 208422 A MY208422 A MY 208422A MY PI2020004677 A MYPI2020004677 A MY PI2020004677A MY PI2020004677 A MYPI2020004677 A MY PI2020004677A MY 208422 A MY208422 A MY 208422A
Authority
MY
Malaysia
Prior art keywords
targeted
combination therapy
antibodies against
against human
variant immunocytokines
Prior art date
Application number
MYPI2020004677A
Inventor
Codarri Deak Laura
Klein Christian
Nicolini Valeria
Umana Pablo
Wullschleger Stephan
Hanahan Douglas
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Priority to MYPI2020004677A priority Critical patent/MY208422A/en
Publication of MY208422A publication Critical patent/MY208422A/en

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to the combination therapy of specific PD-1-targeted IL-2 variant immunocytokines with specific antibodies which bind human PD-L1. [No Suitable Figures]
MYPI2020004677A 2020-09-09 2020-09-09 Combination therapy of pd-1-targeted il-2 variant immunocytokines and antibodies against human pd-l1 MY208422A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
MYPI2020004677A MY208422A (en) 2020-09-09 2020-09-09 Combination therapy of pd-1-targeted il-2 variant immunocytokines and antibodies against human pd-l1

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MYPI2020004677A MY208422A (en) 2020-09-09 2020-09-09 Combination therapy of pd-1-targeted il-2 variant immunocytokines and antibodies against human pd-l1

Publications (1)

Publication Number Publication Date
MY208422A true MY208422A (en) 2025-05-08

Family

ID=96881834

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2020004677A MY208422A (en) 2020-09-09 2020-09-09 Combination therapy of pd-1-targeted il-2 variant immunocytokines and antibodies against human pd-l1

Country Status (1)

Country Link
MY (1) MY208422A (en)

Similar Documents

Publication Publication Date Title
PH12020500671A1 (en) Antibodies specific for gucy2c and uses thereof
ZA202201874B (en) Anti-hla-g antibodies, compositions comprising anti-hla-g antibodies and methods of using anti-hla-g antibodies
PH12020500240A1 (en) Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies
MX379475B (en) Combination therapy of tumor-targeted il-2 variant immunocytokines and antibodies against human pd-l1
MY209474A (en) Il-2 conjugates and methods of use to treat autoimmune diseases
WO2021127487A3 (en) Novel il2 agonists and methods of use thereof
WO2020086647A8 (en) Ny-eso-1 t cell receptors and methods of use thereof
WO2019142149A3 (en) Methods of treating cancers with antagonistic anti-pd-1 antibodies
PH12019501824A1 (en) Anti-gprc5d antibody and molecule comprising the antibody
MY202870A (en) Anti-ctla-4 antibodies and uses thereof
EP4585261A3 (en) Antibodies that specifically bind to human il-15 and uses thereof
CR20210622A (en) Multispecific heavy chain antibodies binding to cd22 and cd3
MY205789A (en) Anti-gdf15 antibodies, compositions and methods of use
WO2020006374A3 (en) Anti-sirp-beta1 antibodies and methods of use thereof
WO2017220989A8 (en) Anti-pd-l1 and il-2 cytokines
MX2023004032A (en) Immuno oncology therapies with il-2 conjugates.
MX2022003005A (en) Anti-cd39 antibody compositions and methods.
WO2019234241A8 (en) ANTI-oxMIF/ANTI-CD3 ANTIBODY FOR CANCER TREATMENT
MY204673A (en) Humanized anti-sirp antibodies
MX2019011624A (en) Methods and compositions for reduction of immunogenicity.
MX2020007555A (en) Factor h potentiating antibodies and uses thereof.
ZA202307404B (en) Anti-met antibodies and uses thereof
WO2019182867A8 (en) Dual specificity antibodies to human pd-l1 and pd-l2 and methods of use therefor
MX2024002069A (en) Anti-hla-g antibodies.
ZA202300222B (en) Anti-αlpha-4-βeta-7 antibodies